Sunbird Bio and Glympse Bio Merge

Sunbird Bio and Glympse Bio Merge to Accelerate Development of Innovative Protein-Based Diagnostic Technologies

Cambridge, MA & Singapore, August 09, 2023 Sunbird Bio, a pioneering biotechnology company focused on advancing the diagnosis and treatment of neurological disorders and early-stage cancer through proprietary protein-based technologies, has successfully merged with Glympse Bio. The merger aims to expedite the development of the two companies protein-based diagnostic platforms, creating a powerful entity named…

Lexington's Cyteir Therapeutics to Close Two Years After IPO

Lexington’s Cyteir Therapeutics to Close Two Years After IPO

A Lexington-based biotech firm, Cyteir Therapeutics Inc., has declared its plan to disband a mere two years following its public debut via an IPO. The company’s announcement on Friday included intends to cease the development of its solitary drug, a clinical-stage program designed to treat ovarian and other solid-tumor cancers. Cyteir aims to liquidate its…